SG10201912394VA - Improved nanoparticle delivery systems - Google Patents
Improved nanoparticle delivery systemsInfo
- Publication number
- SG10201912394VA SG10201912394VA SG10201912394VA SG10201912394VA SG10201912394VA SG 10201912394V A SG10201912394V A SG 10201912394VA SG 10201912394V A SG10201912394V A SG 10201912394VA SG 10201912394V A SG10201912394V A SG 10201912394VA SG 10201912394V A SG10201912394V A SG 10201912394VA
- Authority
- SG
- Singapore
- Prior art keywords
- delivery systems
- nanoparticle delivery
- improved nanoparticle
- improved
- systems
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192973P | 2015-07-15 | 2015-07-15 | |
| US201562252396P | 2015-11-06 | 2015-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912394VA true SG10201912394VA (en) | 2020-02-27 |
Family
ID=57757767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912394VA SG10201912394VA (en) | 2015-07-15 | 2016-07-14 | Improved nanoparticle delivery systems |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10285951B2 (ru) |
| EP (1) | EP3322404A4 (ru) |
| JP (2) | JP2018521068A (ru) |
| KR (1) | KR20180029242A (ru) |
| CN (1) | CN107920985B (ru) |
| AU (2) | AU2016294617B2 (ru) |
| BR (1) | BR112018000217A2 (ru) |
| CA (1) | CA2991062C (ru) |
| CO (1) | CO2018000146A2 (ru) |
| HK (1) | HK1251159A1 (ru) |
| IL (1) | IL256797B (ru) |
| MA (1) | MA42458A (ru) |
| MX (1) | MX2018000611A (ru) |
| RU (1) | RU2018105494A (ru) |
| SG (1) | SG10201912394VA (ru) |
| WO (1) | WO2017011685A1 (ru) |
| ZA (1) | ZA201800130B (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116077439A (zh) | 2016-04-29 | 2023-05-09 | 西奈山伊坎医学院 | 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积 |
| CN112218619A (zh) * | 2017-11-20 | 2021-01-12 | 西奈山伊坎医学院 | 通过治疗性纳米生物制剂组合物抑制驯化免疫 |
| WO2019178443A1 (en) * | 2018-03-16 | 2019-09-19 | University Of Massachusetts | Yeast cell wall particle encapsulation of biodegradable pro-payloads |
| KR102088663B1 (ko) * | 2018-03-20 | 2020-03-13 | 한국세라믹기술원 | 친수성 및 소수성 약물의 동시 전달을 위한 온도민감성 나노스펀지 플랫폼 및 이의 용도 |
| WO2020123481A1 (en) * | 2018-12-10 | 2020-06-18 | Celator Pharmaceuticals Inc. | Combination formulations of taxanes and mtor inhibitors |
| KR20220045203A (ko) * | 2019-08-13 | 2022-04-12 | 펩티노보 바이오파마, 인크. | 암 치료에 따른 화학요법-유도된 말초 신경병증 치료를 위한 palm |
| WO2022055542A1 (en) * | 2020-09-10 | 2022-03-17 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing pd-1 antagonist prodrugs useful in the treatment of cancer and methods thereof |
| US11859021B2 (en) | 2021-03-19 | 2024-01-02 | Icahn School Of Medicine At Mount Sinai | Compounds for regulating trained immunity, and their methods of use |
| WO2025199353A1 (en) * | 2024-03-21 | 2025-09-25 | Purdue Research Foundation | Nanoparticulate formulations and foliar administration thereof in the treatment and prevention of citrus greening disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1432402E (pt) | 2001-10-03 | 2007-02-28 | Celator Pharmaceuticals Inc | Composições para administração de combinações de fármacos |
| EP1448231A1 (en) | 2001-11-19 | 2004-08-25 | Control Delivery Systems, Inc. | Topical delivery of codrugs |
| AU2003223226A1 (en) * | 2003-02-20 | 2004-09-17 | University Of Connecticut Health Center | Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease |
| AU2005269800B8 (en) * | 2004-07-19 | 2011-12-01 | Celator Pharmaceuticals, Inc. | Particulate constructs for release of active agents |
| AU2006235538A1 (en) * | 2005-04-12 | 2006-10-19 | Wisconsin Alumni Research Foundation | Micelle composition of polymer and passenger drug |
| EP2222278B1 (en) * | 2007-11-28 | 2015-04-08 | Celator Pharmaceuticals, Inc. | Improved taxane delivery system |
| BRPI1014854A2 (pt) * | 2009-03-30 | 2016-05-03 | Cerulean Pharma Inc | "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados" |
| CA2779843A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| EA201390144A1 (ru) * | 2010-08-20 | 2013-06-28 | Серулин Фарма Инк. | Конъюгаты терапевтический пептид-полимер, частицы, композиции и связанные с ними способы |
| EA201390740A1 (ru) | 2010-11-19 | 2013-12-30 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Способ лечения с использованием ингибитора braf |
| AU2012249553A1 (en) * | 2011-04-29 | 2013-10-24 | Selecta Biociences, Inc. | Tolerogenic synthetic nanocarriers for allergy therapy |
| US20140308363A1 (en) * | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| DE102011109374A1 (de) * | 2011-08-04 | 2013-02-07 | Bock 1 Gmbh & Co. Kg | Stuhl mit Wippmechanik |
| KR102062025B1 (ko) * | 2014-06-30 | 2020-01-03 | 타베다 세라퓨틱스, 인코포레이티드 | 표적화된 콘주게이트 및 입자 및 그것의 제형 |
-
2016
- 2016-07-14 SG SG10201912394VA patent/SG10201912394VA/en unknown
- 2016-07-14 HK HK18110619.0A patent/HK1251159A1/zh unknown
- 2016-07-14 US US15/744,723 patent/US10285951B2/en active Active
- 2016-07-14 RU RU2018105494A patent/RU2018105494A/ru not_active Application Discontinuation
- 2016-07-14 CN CN201680041368.XA patent/CN107920985B/zh active Active
- 2016-07-14 WO PCT/US2016/042330 patent/WO2017011685A1/en not_active Ceased
- 2016-07-14 BR BR112018000217A patent/BR112018000217A2/pt not_active Application Discontinuation
- 2016-07-14 MA MA042458A patent/MA42458A/fr unknown
- 2016-07-14 KR KR1020187004307A patent/KR20180029242A/ko not_active Ceased
- 2016-07-14 EP EP16825199.9A patent/EP3322404A4/en not_active Withdrawn
- 2016-07-14 CA CA2991062A patent/CA2991062C/en active Active
- 2016-07-14 AU AU2016294617A patent/AU2016294617B2/en active Active
- 2016-07-14 JP JP2018500438A patent/JP2018521068A/ja not_active Withdrawn
- 2016-07-14 MX MX2018000611A patent/MX2018000611A/es unknown
-
2018
- 2018-01-08 IL IL256797A patent/IL256797B/en active IP Right Grant
- 2018-01-08 ZA ZA2018/00130A patent/ZA201800130B/en unknown
- 2018-01-09 CO CONC2018/0000146A patent/CO2018000146A2/es unknown
-
2019
- 2019-03-15 US US16/355,594 patent/US20190209484A1/en not_active Abandoned
-
2020
- 2020-09-04 US US17/013,101 patent/US11413253B2/en active Active
-
2021
- 2021-11-08 JP JP2021181961A patent/JP2022033751A/ja active Pending
- 2021-12-16 AU AU2021286353A patent/AU2021286353A1/en not_active Abandoned
-
2022
- 2022-07-15 US US17/812,832 patent/US20240366519A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20240366519A1 (en) | 2024-11-07 |
| JP2018521068A (ja) | 2018-08-02 |
| BR112018000217A2 (pt) | 2018-09-04 |
| RU2018105494A3 (ru) | 2019-12-17 |
| CA2991062C (en) | 2023-06-20 |
| US20180207104A1 (en) | 2018-07-26 |
| EP3322404A4 (en) | 2019-03-20 |
| RU2018105494A (ru) | 2019-08-15 |
| US20190209484A1 (en) | 2019-07-11 |
| AU2016294617A1 (en) | 2018-01-25 |
| CN107920985A (zh) | 2018-04-17 |
| KR20180029242A (ko) | 2018-03-20 |
| JP2022033751A (ja) | 2022-03-02 |
| US10285951B2 (en) | 2019-05-14 |
| CO2018000146A2 (es) | 2018-04-19 |
| AU2016294617B2 (en) | 2021-09-16 |
| CN107920985B (zh) | 2022-03-01 |
| AU2021286353A1 (en) | 2022-01-20 |
| HK1251159A1 (zh) | 2019-01-25 |
| CA2991062A1 (en) | 2017-01-19 |
| IL256797B (en) | 2021-05-31 |
| MX2018000611A (es) | 2018-09-06 |
| MA42458A (fr) | 2018-05-23 |
| US20210052508A1 (en) | 2021-02-25 |
| US11413253B2 (en) | 2022-08-16 |
| WO2017011685A1 (en) | 2017-01-19 |
| IL256797A (en) | 2018-06-28 |
| ZA201800130B (en) | 2018-12-19 |
| EP3322404A1 (en) | 2018-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201802837D0 (en) | Awrosol delivery system | |
| ZA201502203B (en) | Nano particulate delivery system | |
| EP3212173A4 (en) | Delivery systems | |
| GB201600232D0 (en) | Fluid delivery system | |
| ZA201800130B (en) | Improved nanoparticle delivery systems | |
| GB201514510D0 (en) | Delivery vehicle | |
| SG11201801783VA (en) | Intracellular delivery vehicle | |
| GB201703170D0 (en) | Improved goods delivery systems | |
| GB201407614D0 (en) | Content delivery system | |
| HUE047207T2 (hu) | Bortezomib alapú adagolórendszer | |
| GB201600229D0 (en) | Fluid delivery system | |
| IL247106A0 (en) | Material delivery system | |
| GB2559712B (en) | Solid state delivery system | |
| GB201715590D0 (en) | Delivery system | |
| IL246874A0 (en) | drug delivery system | |
| GB201420903D0 (en) | Fluids delivery system | |
| GB2532245B (en) | Cardioplegic agent delivery system | |
| GB201509934D0 (en) | Nanoparticles | |
| GB201517654D0 (en) | Object delivery system | |
| GB201600236D0 (en) | Fluid delivery system | |
| GB201614126D0 (en) | Delivery vehicle | |
| GB201522636D0 (en) | Delivery system | |
| IL256995A (en) | Transdermal delivery system | |
| IL256994A (en) | Transdermal delivery system | |
| GB201721699D0 (en) | Delivery system |